Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
Sharma GG, Cortinovis D, Agustoni F, Arosio G, Villa M, Cordani N, Bidoli P, Bisson WH, Pagni F, Piazza R, Gambacorti-Passerini C, Mologni L. Sharma GG, et al. Among authors: piazza r. J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028. J Thorac Oncol. 2019. PMID: 31668326 Free article. No abstract available.
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.
Gambacorti-Passerini C, Piazza R, D'Incalci M. Gambacorti-Passerini C, et al. Among authors: piazza r. Blood. 2003 Sep 1;102(5):1933-4; author reply 1934-5. doi: 10.1182/blood-2003-05-1629. Blood. 2003. PMID: 12930735 Free article. No abstract available.
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Piazza RG, et al. Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5. doi: 10.1016/j.bcmd.2006.06.002. Epub 2006 Aug 14. Blood Cells Mol Dis. 2006. PMID: 16908206 Clinical Trial.
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. Puttini M, et al. Among authors: piazza r. Cancer Res. 2006 Dec 1;66(23):11314-22. doi: 10.1158/0008-5472.CAN-06-1199. Epub 2006 Nov 17. Cancer Res. 2006. PMID: 17114238
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella-Deana A, Marin O, Perrotti D, Gambacorti-Passerini C. Galietta A, et al. Blood. 2007 Oct 1;110(7):2600-9. doi: 10.1182/blood-2006-01-028647. Epub 2007 May 30. Blood. 2007. PMID: 17537995 Free PMC article.
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.
Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C. Mologni L, et al. Among authors: piazza r. Int J Cancer. 2009 Apr 15;124(8):1990-6. doi: 10.1002/ijc.24158. Int J Cancer. 2009. PMID: 19123474
519 results